Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
24 Results for "
LIP
" in MedChemExpress (MCE) Product Catalog:
Products (24)
24 Results for "LIP" in MCE Product Catalog:
45
45 Publications Verification
Cat. No.: HY-D1533
CAS No.: 1447815-38-4
1
1 Cited Publications
Synonyms: 3,4-Dimethoxybenzyl alcohol
Target:
1
Cat. No.: HY-DY1030
CAS No.: 1447815-38-4
Solvent and concentration: DMSO: 5 mM
Cat. No.: HY-N5008
CAS No.: 146100-02-9
Cat. No.: HY-113499B
Target:
연구분야:
cis-Malonylcarnitine lithium is an ester compound and a metabolite of Malonyl CoA (HY-115899). The level of cis-Malonylcarnitine lithium is closely related to some diseases, such as malonic aciduria, non-syndromic cleft lip with or without cleft palate, etc .
Category:
Alkaloids Quinolizidine Alkaloids Rubiaceae Mitragyna speciosa Korth. Plants Indole Alkaloids
Target:
Category:
Cat. No.: HY-B1234A
CAS No.: 83834-59-7
Synonyms: (E)-Octyl methoxycinnamate
연구분야:
(E)-Octinoxate is the isomer of Octinoxate (HY-B1234). Octinoxate is an organic compound that is an ingredient in some sunscreens and lip balms, primarily used is in sunscreens and other cosmetics to absorb UV-B rays from the sun, protecting the skin from damage and can be used to reduce the appearance of scars. Octinoxate also has a complex androgenic and estrogenic effect .
Cat. No.: HY-144825
연구분야:
Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function .
Cat. No.: HY-W738271
CAS No.: 91384-88-2
Synonyms: 3,4-Dimethoxybenzyl alcohol-13C
Cat. No.: HY-RS13430
Target:
연구분야:
SMG1 Human Pre-designed siRNA Set A contains three designed siRNAs for SMG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-170991
연구분야:
C12-rrw-NH2 (Compound Lip7) is an antibacterial agent against gram-positive bacteria, especially against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). C12-rrw-NH2 induces bacterial death via depolarizing the bacterial cytoplasmic membrane, disrupting the integrity of the bacterial membrane, leading to leakage of nucleic acid and protein and promoting the generation of Reactive Oxygen Species. C12-rrw-NH2 is potential to be used for research of developing high-stability antimicrobial peptides .
Cat. No.: HY-N18763
CAS No.: 85940-30-3
Cat. No.: HY-RS17419
Target:
연구분야:
Cebpb Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cebpb gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-182988
CAS No.: 2681258-65-9
L-Arg-DSPE is an arginine-functionalized DSPE lipid containing free guanidine groups. L-Arg-DSPE serves as a component of NO-responsive degradable drug-loaded liposomal nanomotors (L-Arg@Lip-DOX), promoting drug deep tumor tissue penetration and cellular internalization. L-Arg-DSPE can be used for the research of drug delivery .
Cat. No.: HY-P82776A
Synonyms: Cleft LIP and palate transmembrane protein 1
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
